Emmaus Life Sciences, Inc. (EMMA): Revenue
$12.45M
Year ended 2025-12-31
$15.53M
Trailing 12 months to 2026-06-30
-12.2%
3-year compound annual growth
-11.7%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.45M | -25.2% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $16.65M | -43.7% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $29.60M | +60.9% | 2025-04-14, From 2023-01-01 |
| 2022-12-31 | $18.39M | -10.8% | 2024-07-03, From 2022-01-01 |
| 2021-12-31 | $20.61M | -11.0% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $23.17M | +1.8% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $22.75M | +38.2% | 2021-08-10, From 2019-01-01 |
| 2018-12-31 | $16.46M | n/a | 2021-01-25, From 2018-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $12.45M | -25.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $12.14M | +73.4% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $13.00M | +85.7% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $13.11M | +29.8% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $13.19M | n/a |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $11.51M | -1.5% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $13.79M | -12.2% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $13.86M | -14.2% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $14.08M | +128.2% |
Compare EMMA, PRLD, EVMN, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗